Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-FF58 in advanced solid tumors
NCT05977322Phase 1Terminated
- Sponsor
- Novartis
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of lutetium Lu 177 FF58 in pancreatic ductal adenocarcinoma (PDAC), gastroesophageal adenocarcinoma and glioblastoma multiforme (GBM), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 6 weeks, Adverse Events at 180 days and 2 more. Started Oct 2023; status: terminated.
02
Drugs
lutetium Lu 177 FF58
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)gastroesophageal adenocarcinomaglioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05977322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05977322.